Article Text

Download PDFPDF
PGI2-induced Th17 cell differentiation in connective tissue disease: a comment
  1. Yaguo Zheng,
  2. Changming Xiong,
  3. Jianguo He
  1. Peking Union Medical College, Fuwai Hospital, Beijing, China
  1. Correspondence to Dr Jianguo He, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardio-Vascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China; Zhengyaguo{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dear Editor

We read with interest the study conducted by Truchetet et al on the regulation of prostaglandin I2 (PGI2) in Th17 cell differentiation in systemic sclerosis (SSc). Actually, previous in vitro studies have found that synthetic PGI2 enhanced Th17 cell differentiation.1 Zhou et al2 have also demonstrated that PGI2 induced Th17 cell differentiation through modulating the ratio of interleukin 23 (IL-23)/interleukin 12 in a mouse model of experimental autoimmune encephalitis. However, in this study, Truchetet et al3 treated SSc-related digital ulcers with iloprost, providing evidence for the first time that iloprost increases the frequency of Th17 cells in human …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.